FDA Clears IMDx C. Difficile Assay for Abbott m2000 System | GenomeWeb

NEW YORK (GenomeWeb News) – IntelligentMDx today said that the US Food and Drug Administration has cleared its C. difficile assay for the Abbott m2000 system.

The assay, the third to receive FDA clearance for use on Abbott's platform in the past three months, detects nucleic acids encoding the toxin A gene and toxin B gene sequences of toxigenic strains of Clostridium difficile in human liquid or soft stool specimens in patients suspected of having C. difficile-associated illnesses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.